Derivation of a Composite Measure of Embedded Symptom Validity Indices (original) (raw)
Related papers
Psychotherapy and Psychosomatics, 2020
Introduction: Patient-reported outcomes (PROs) are of increasing importance in clinical medicine. However, their evaluation by classic psychometric methods carries considerable limitations. The clinimetric approach provides a viable framework for their assessment. Objective: The aim of this paper was to provide a systematic review of clinimetric properties of the Symptom Questionnaire (SQ), a simple, self-rated instrument for the assessment of psychological symptoms (depression, anxiety, hostility, and somatization) and well-being (contentment, relaxation, friendliness, and physical well-being). Methods: The PRISMA guidelines were used. Electronic databases were searched from inception up to March 2019. Only original research articles, published in English, reporting data about the clinimetric properties of the SQ, were included. Results: A total of 284 studies was selected. The SQ has been used in populations of adults, adolescents, and older individuals. The scale significantly discriminated between subgroups of subjects in both clinical and nonclinical settings, and differentiated medical and psychiatric patients from healthy controls. In longitudinal studies and in controlled pharmacological and psychotherapy trials, it was highly sensitive to symptoms and well-being changes and discriminated between the effects of psychotropic drugs and placebo. Conclusions: The SQ is a highly sensitive clinimetric index. It may yield clinical information that similar scales would fail to provide and has a unique position among the PROs that are available. Its use in clinical trials is strongly recommended.
Psychometric Properties of the Turkish Brief Symptom Measure-25
The Brief Symptom Measure-25 (BSM-25) is a quick and self-administrated measurement, which was originally developed to assess general psychiatric symptomatolo-gy. The aim of the present study was to examine the psycho-metric properties of the Turkish BSM-25. The non-clinical sample consisted of 382 adult participants (71.5% were female) and the clinical sample consisted of 42 adult participants (76.2% were female). To test the psychometric properties of the Turkish BSM-25, we performed a series of analyses including basic explanatory factor analysis, bifactor modeling, bivariate correlation, one-way ANOVA, and ROC analysis. The results indicated that the Turkish BSM-25 had a high level of internal consistency (.92) and acceptable fit indices (RMSEA = .07, CFI = .95 GFI = .97 NNFI = .94). Furthermore, the Turkish BSM-25 successfully discriminated the clinical and non-clinical samples and showed strong validity. The cutoff score was 70.50. In conclusion, the present study provided empirical support for the psychometric adequacy of the Turkish BSM-25 and yielded one general factor.
The Brief Negative Symptom Scale: Psychometric Properties
Schizophrenia Bulletin, 2011
The participants in the NIMH-MATRICS Consensus Development Conference on Negative Symptoms recommended that an instrument be developed that measured blunted affect, alogia, asociality, anhedonia, and avolition. The Brief Negative Symptom Scale (BNSS) is a 13-item instrument designed for clinical trials and other studies that measures these 5 domains. The interrater, test-retest, and internal consistency of the instrument were strong, with respective intraclass correlation coefficients of 0.93 for the BNSS total score and values of 0.89-0.95 for individual subscales. Comparisons with positive symptoms and other negative symptom instruments supported the discriminant and concurrent validity of the instrument.
Brief Symptom Inventory - Test Review
D. Forms; groups to which applicable: The Brief Symptom Inventory (BSI) was derived from the Symptom Checklist-90-Revised which was the first derivative of the Hopkins Symptom Checklist . There is also an 18-item short form questionnaire. It is intended for use with adult non-patients, adult psychiatric outpatients, adult psychiatric inpatients and adolescent nonpatients of at least 13 years in age. It requires a 6 th grade reading level and the author states that the BSI can be reliably administered in a narrative mode to patients who cannot read. It is available in English or Spanish and French for Canada as well as several other languages.
Symptom validity assessment in European countries: Development and state of the art
Clínica y Salud, 2013
In the past, the practice of symptom validity assessment (SVA) in European countries was considerably lagging behind developments in North America, with the topic of malingering being largely taboo for psychological and medical professionals. This was being changed in the course of the past decade with a growing interest in methods for the assessment of negative response bias. European estimates of suboptimal test performance in civil and social forensic contexts point at base rates similar to those obtained in North America. Symptom over-reporting and underperformance in neuropsychological examinations appear to occur in a sizable proportion of patients. Although there is considerable progress in establishing SVA as an integral and indispensable part of psychological and neuropsychological assessment in some countries, others appear to lag behind. In some countries there is still enormous resistance against SVA from part of the neuropsychological and psychiatric communities.